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MJA PRACTICE ESSENTIALS — INFECTIOUS DISEASES
Who can be treated at home, and who needs to be in hospital? 
FEW INFECTIONS GENERATE as much controversy as
community-acquired pneumonia. Reasons for this include
the range of possible pathogens, difficulty in determining
which pathogen to target when choosing an antibiotic, the
variety of av ilable antibio ics and increasing antibiotic
resistance. In this article, we have tried to balance the needs
of the individual patient with the need to control healthcare
costs and antibiotic resistance. Our recommendations are
restricted to the management of adults.
Epidemiology
Community-acquired pneumonia (CAP) is commonly
defined as an acute infection of the lower respiratory tract
occurring in a patient who has not resided in a hospital or
healthcare facility in the previous 14 days.1 Current
approaches to the empirical management of CAP emphasise
the type of patient (“community” or “hospital”), rather than
the type of symptoms (“typical” or “atypical”). 
We lack detailed information on the incidence of CAP in
Australia, but in the United States CAP requiring hospital
admission occurs in about 258 per 100 000 population per
year, rising to 962 per 100 000 among those aged 65 years or
over.1 Mortality rates in recent years appear to have
increased. Mortality averages 14%, but is less than 1% for
those not requiring admission to hospital.1
Pathogenesis and risk factors
Although inhalation and micro-aspiration constantly deliver
potential pathogens, the respiratory tract below the larynx is
normally sterile. Sterility is maintained by host defence
systems, which include innate and acquired immunity and
the mucociliary transport system. Factors that perturb these
systems or predispose to aspiration increase the risk of
pneumonia.
In community studies in Finland, the rate of CAP
increased for each year of age over 50 years; other risk
factors were alcoholism, asthma, immunosuppression, and
institutionalisation.1 In the United States, studies of risk
factors for infection with Streptococcus pneumoniae have
implicated dementia, seizure disorders, smoking, heart
failure, stroke and chronic obstructive pulmonary disease.2
In Australia, Indigenous people have an increased risk of
admission to hospital with CAP3,4 and of pneumococcal
pneumonia5 (Box 1). Studies in Victoria have shown that
pneumococcal pneumonia is common in active elderly
people, not only in the sick and infirm.6 
Causative organisms
Many pathogens can cause CAP. A South Australian study
of 106 adults admitted to hospital with CAP in 1987–1988
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Abstract
■ Community-acquired pneumonia is caused by a range of 
organisms, most commonly Streptococcus pneumoniae, 
Mycoplasma pneumoniae, Chlamydia pneumoniae and 
respiratory viruses. 
■ Chest x-ray is required for diagnosis.
■ A risk score based on patient age, coexisting illness, 
physical signs and results of investigations can aid 
management decisions. 
■ Patients at low risk can usually be managed with oral 
antibiotics at home, while those at higher risk should be 
further assessed, and may need admission to hospital 
and intravenous therapy.
■ For S. pneumoniae infection, amoxycillin is the 
recommended oral drug, while benzylpenicillin is 
recommended for intravenous use; all patients should 
also receive a tetracycline (eg, doxycycline) or macrolide 
(eg, roxithromycin) as part of initial therapy. 
■ Flucloxacillin or dicloxacillin should be added if 
staphylococcal pneumonia is suspected, and gentamicin 
or other specific therapy if gram-negative pneumonia is 
suspected; a third-generation cephalosporin plus 
intravenous erythromycin is recommended as initial 
therapy for severe cases.
■ Infections that require special therapy should be 
considered (eg, tuberculosis, melioidosis, Legionella, 
Acinetobacter baumanii and Pneumocystis carinii 
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found that the most common cause was S. pneumoniae
(“pneumococcus”) (42%), followed by respiratory viruses
(18%), Haemophilus influenzae (9%), Mycoplasma pneumo-
niae and enteric gram-negative bacteria (8% each),
Chlamydia psittaci (5%), Staphylococcus aureus, Legionella
spp. and Mycobacterium tuberculosis (3% each).7 More recent
overseas studies have shown that S. pneumoniae is still the
most common pathogen overall, followed possibly by M.
pneumoniae and Chlamydia pneumoniae.1,2 In ambulatory
care, the proportion of patients with pathogens such as M.
pneumoniae and C. pneumoniae that do not respond to
penicillin, amoxycillin or cephalosporins may approach
50%.8 
Race, geographic location, lifestyle and country of origin
influence the expected aetiology of CAP. For example,
pneumococcal pneumonia occurs at high rates in Indige-
nous Australians, while Burkholderia pseudomallei (melioido-
sis) and Acinetobacter baumanii are important causes of CAP
in people in tropical Australia,9,10 as is tuberculosis in people
born overseas. HIV infection should be considered in
patients with recurrent pneumococcal pneumonia. Pneumo-
cystis carinii infection may be the cause of an unusually
prolonged dry cough in a patient with HIV risk factors.
Aspiration pneumonia is an important variant of
community-acquired pneumonia that occurs particularly in
elderly people and those with conditions such as bulbar
weakness, laryngectomy or stroke. Pulmonary segments that
are lowermost at the moment of aspiration are involved. The
most common causative organisms identified in recent
studies were S. aureus, H. influenzae and gram-negative




CAP should be considered when a patient presents with two




■ change in sputum colour if there is a chronic cough;
■ chest discomfort; or
■ dyspnoea.
However, many patients who satisfy these criteria do not
have pneumonia, and failure to distinguish pneumonia from
acute bronchitis is an important reason for overuse of
antibiotics.1,2 Furthermore, CAP can present with fever
without localising features, and some patients may have no
fever (eg, elderly patients may present only with a sudden
change in functional status). 
Thus, if pneumonia is being considered, a chest x-ray is
needed. No set of decision rules is as yet superior to clinical
judgement when deciding whom to x-ray.13 Physical signs of
consolidation are suggestive but are often not found at
presentation. Nevertheless, some clinical signs, such as
confusion, should be specifically noted because of their
prognostic value14,15 (see Risk stratification). 
1: Factors that increase risk of community-acquired 
pneumonia2-5
Age over 50 years
Alcoholism
Asthma










2: Chest x-ray in Streptococcus pneumoniae pneumonia
Chest x-ray is the cardinal investigation in community-acquired pneumonia, but may occasionally be misleading.
At presentation: A 47-year-old smoker presented after just a few hours 
of rigors and productive cough. Despite clinical signs of right upper 
zone consolidation, chest x-ray showed only minor abnormalities. 
Empirical therapy for community-acquired pneumonia was begun. 
12 hours later: Chest x-ray showed consolidation in the right upper lobe 
consistent with the earlier clinical signs. S. pneumoniae was isolated 
from blood cultures. The patient recovered fully. (X-rays courtesy of Dr 
Bryan Speed, Fairfield Hospital Historical Collection, Melbourne, VIC.)
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Investigations
Chest x-ray: This is the cardinal investigation. In the
appropriate setting, a new area of consolidation on chest x-
ray makes the diagnosis, but x-ray is a poor guide to the
likely pathogen. Other causes of a new lung infiltrate on
chest x-ray include atelectasis, non-infective pneumonitis,
haemorrhage and cardiac failure. Occasionally, the chest x-
ray initially appears normal (eg, in the first few hours of S.
pneumoniae pneumonia and early in HIV-related P. carinii
pneumonia) (Box 2).
Sputum microscopy and culture: There is debate about the
value of sputum samples in diagnosis of CAP. Oral flora
rather than the offending pathogen may dominate a sputum
Gram stain and culture. Nevertheless, we believe that an
attempt should be made to obtain a sputum sample before
beginning antibiotic therapy, as this is sometimes the best
opportunity to identify pathogens that need special
treatment. Microscopy and culture for M. tuberculosis should
be requested if the patient was born overseas.
Blood chemistry and haematology: All patients with CAP
being assessed in emergency departments or admitted to
hospital should have oximetry, measurement of serum
electrolytes and urea levels, and a full blood count to assist in
assessing severity. Blood gas measurement is also recom-
mended, as it provides prognostic information (pH and
PaO2) and may identify patients with ventilatory failure or
chronic hypercapnia (PaCO2). If the patient has known or
suspected diabetes mellitus, measurement of blood glucose
also assists in assessing severity.
Blood culture: Blood cultures are the most specific diagnos-
tic test for the causative organism, but are positive in only
around 10% of patients admitted to hospital with CAP.1 The
more severe the pneumonia, the more likely blood cultures
are to be positive.16 We recommend that blood be cultured
from all patients, except those well enough to be managed at
home with oral antibiotics. 
Other investigations: The Legionella urinary antigen test
is rapid, reliable and has a high degree of sensitivity and
specificity.17 It should be performed in all patients with CAP,
except perhaps those with low enough risk to be managed at
home with empirical oral therapy (see Risk stratification).
However, the test detects only Legionella pneumophila
serogroup 1, which accounts for only half of all cases of
Legionella pneumonia. 
Viral immunofluorescence testing of a nasopharyngeal
aspirate is rapid and useful if it detects influenza or
respiratory syncytial virus. Virus detection does not preclude
a secondary bacterial invader.
Serological diagnosis requires acute and convalescent
serum samples and is therefore not useful in acute
management of CAP. Some laboratories offer acute serodiag-
nosis for M. pneumoniae, but these tests may lack specificity.18
Even after extensive investigations, the microbial cause of
CAP is revealed in only about half of all patients.1,2 New
diagnostic tests are under development. The most promising
are rapid screens that can be performed on throat swabs,
using polymerase chain reaction.
Management
CAP is common, and many patients will recover with a
simple oral antibiotic regimen, or even without antibiotics.
However, a small proportion are at significant risk of death.
Questions to be considered after radiological confirmation
of CAP are:
■ What is the severity?
■ Where should the patient be managed?
■ Which antibiotics should be used?
Risk stratification
Risk-stratification systems can help answer these questions.
One approach is to refer to a list of mortality risk factors
(Box 3). A New Zealand study found that patients with CAP
who had at least two key features on admission (diastolic
blood pressure  60 mmHg, respiratory rate  30 per
minute, serum urea level > 7 mmol/L, or confusion) were 36
times more likely to die than those without these features.15 
In the United States, a prospectively validated severity
prediction score is increasingly used — the Pneumonia
Severity Index (PSI).19,20 The method of scoring this index
is shown in Box 4, and risk of death in different PSI risk
classes in Box 5. The rule was derived in patients aged over
18 years who were HIV-antibody negative and had not been
in hospital during the previous seven days, although they
included nursing home residents. Strictly, the PSI score
identifies predictors of mortality and was not originally





Identifiable at initial assessment
Hypothermia (temperature  37C) 5.0
Hypotension (systolic blood pressure <100 mmHg) 4.8
Existing neurological disease 4.6
More than one lobe involved on chest x-ray 3.1
Tachypnoea (respiratory rate 20 per min) 2.9
Existing neoplastic disease 2.8
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designed to triage patients or guide prescribing. However,
high PSI scores correlate with admission to hospital and an
intensive care unit, and there is limited evidence that the
score correctly identifies patients who can be safely managed
in the community with oral antibiotics.20 
A suggested protocol for determining patient risk and
management using the PSI score is shown in Box 6. We
recommend that all but the lowest-risk patients (PSI risk
class I) be further assessed. Whenever practicable, this
assessment should be in an emergency department with
rapid access to laboratory results. To apply the PSI
algorithm, blood pH must be estimated; while pulse
oximetry measurement of O2 saturation can substitute for
pO2, until recently there has been no alternative to arterial
blood gas measurement to assess pH. A recent Australian
study showed that pH obtained by rapid analysis of a venous
blood sample is a good approximation of arterial blood
pH.21 Therefore, if arterial blood gas cannot be measured,
O2 saturation plus venous blood pH could be substituted.
Risk-stratification systems, such as the PSI score, should
not replace good clinical judgement. For example, a
homeless low-risk patient should not be sent “home” on oral
antibiotics, and a patient who is vomiting should not be
treated with oral therapy. In addition, the original
description of the PSI score contained the important caveat
that all patients with hypoxia in room air (O2 saturation
<90% or pO2 <60 mmHg) or unusual comorbidities not
specifically scored (eg, severe neuromuscular disease)
should be admitted to hospital, regardless of PSI score.19
Antibiotic choice
Antibiotic resistance trends: In Australia, some organisms
that cause CAP are increasingly resistant to antibiotics.
However, laboratory resistance does not automatically
correlate with treatment failure. For example, although
about 20% of clinical isolates of S. pneumoniae now have
reduced susceptibility to penicillin,22 most of this resistance
is “intermediate”, meaning that CAP is likely to respond to
oral amoxycillin or parenteral benzylpenicillin. Clinical
failure of penicillins in respiratory infection caused by S.
pneumoniae is unlikely unless the penicillin minimum
inhibitory concentration exceeds 4 mg/L (high-level resist-
ance).23 Such strains are still rare in Australia. In contrast,
treatment has failed in cases of meningitis caused by S.
pneumoniae with intermediate resistance,24 because of the
additional problem of drug penetration to the cerebrospinal
fluid. Third-generation cephalosporins may also fail against
these strains. S. pneumoniae may also be resistant to
trimethoprim–sulfamethoxazole (42% of clinical isolates),
tetracyclines (15%) and erythromycin (11%).25
Resistance to amoxycillin is steadily increasing in H.
influenzae and is currently about 25%. Resistance of
Mycoplasma, Chlamydia and Legionella species to their drugs
of choice is rare.
Low-risk patients: For patients at low risk (risk class I and
many patients in classes II and III, corresponding to PSI
score < 90), management with oral antibiotic therapy in the
community is probably appropriate, provided they are not
hypoxic and their social circumstances are suitable. Regular
4: Patient classification using Pneumonia Severity 
Index (PSI)19
PSI risk class I (lowest risk). Patient has none of the following:
■ Age > 50 years;
■ History of neoplastic disease, congestive cardiac failure, 
cerebrovascular, renal or liver disease; or
■ Clinical signs — altered mental state, pulse rate 125 per 
minute, respiratory rate  30 per minute, systolic blood pressure 
< 90 mmHg, or temperature <35C or 40C.
PSI risk classes II–V. Patients with any of the above characteristics 
are classified according to their PSI score, calculated according to 
the table below.
Calculation of PSI risk score
Factor PSI score
Patient age Age in years (male)
or age – 10 (female)
Nursing home resident +10
Coexisting illnesses
 Neoplastic disease +30
 Liver disease +20
 Congestive cardiac failure +10
 Cerebrovascular disease +10
 Renal disease +10
Signs on examination
 Altered mental state +20
 Respiratory rate 30 per minute +20
 Systolic blood pressure <90 mmHg +20
 Temperature 35C or 40C +15
 Pulse rate 125 bpm +10
Results of investigations
 Arterial pH <7.35 +30
 Serum urea level 11 mmol/L +20
 Serum sodium level <130 mmol/L +10
 Serum glucose level 14 mmol/L +10
 Haematocrit <30% +10
 PO2 <60 mmHg or O2 saturation <90% +10
 Pleural effusion +10
5: Mortality within 30 days according to PSI risk 
class19
Risk class Score Mortality
I Score not calculated 0.1%




PSI = Pneumonia Severity Index.
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review is essential. We recommend a combination of
amoxycillin and either roxithromycin or doxycycline (the
latter should be avoided in pregnancy).
Amoxycillin is aimed at S. pneumoniae, as this is still the
single most likely pathogen, and is preferable to penicillin as
absorption and dosing frequency are more favourable.
Doxycycline and roxithromycin are usually effective against
other potential pathogens not covered by amoxycillin, which
are common in ambulatory patients. Resistance of S.
pneumoniae to these agents is more likely to be clinically
significant than resistance to penicillin or amoxycillin. We
believe that pneumococcal resistance to roxithromycin and
doxycycline is now too common in Australia to recommend
use of one of these agents alone for CAP. In this respect, our
recommendations differ from those of the 11th version of
Therapeutic guidelines: antibiotic.26
In patients with penicillin allergy, oral cephalexin or
cefaclor should probably not be used, as their coverage of S.
pneumoniae with reduced penicillin susceptibility is subopti-
mal. Sole reliance on a macrolide or tetracycline is also not
recommended for the reasons above. An option for these
patients is a combination of either oral cefuroxime axetil or
outpatient intravenous ceftriaxone (which can be given once
daily) with oral roxithromycin or doxycycline. Another
option is single-agent therapy with one of the new
fluoroquinolones — moxifloxacin or gatifloxacin — as these
agents are effective against all common pathogens. However,
they are not yet available on the Pharmaceutical Benefits
Scheme, are expensive compared with standard oral therapy,
and their overuse could generate resistance to valuable
reserve agents, such as ciprofloxacin.
Higher-risk patients:  Patients at higher risk (PSI risk class IV
and some patients in other classes) require intravenous
therapy. Intravenous benzylpenicillin plus oral roxithromy-
cin or doxycycline still provide excellent cover for almost all
pathogens, except S. aureus and gram-negative organisms
(case report, Box 7). Flucloxacillin or dicloxacillin should be
added if staphylococcal pneumonia is suspected (ie, recent
influenza, sputum Gram stain shows gram-positive cocci
resembling staphylococci, or blood or sputum cultures yield
S. aureus). Similarly, gram-negative rods in the sputum or
blood should prompt immediate addition of an aminoglyco-
side or extended-spectrum cephalosporin.
Highest-risk patients: For patients at highest risk of death
(PSI risk class V), early broad-spectrum parenteral therapy
is essential. Failure to include antibiotics effective against the
pathogen in the initial regimen worsens prognosis.1 
Intravenous erythromycin plus ceftriaxone or cefotaxime
has been recommended for severe CAP by Therapeutic
guidelines: antibiotic for several years. In contrast, the 11th
(2000) version recommends intravenous erythromycin plus
penicillin and gentamicin, with the previous regimen
reserved for patients with penicillin allergy.24 A recent non-
randomised comparison in Australia suggested that the two
regimens may be equivalent,27 but a properly powered,
randomised study is required to settle the issue.28 Until
better evidence is available, we continue to recommend
intravenous erythromycin plus either ceftriaxone or cefotax-
ime in these very unwell patients. It is also necessary to
consider carefully the possibility of specific pathogens which
may require additional therapy (eg, S. aureus, Pseudomonas
spp., other gram-negative organisms and P. carinii).
Tropical Australia: Patients in tropical Australia, particularly
those with more severe pneumonia, may be infected with B.
6: Diagnosis and management of community-
acquired pneumonia in adults*
PSI = Pneumonia Severity Index. IV = intravenous.
* Adapted from Fine et al.19
† Assessment in the community may be appropriate if access to an emergency 
department is limited by time or distance.
‡ With the exception that patients with hypoxia in room air (O2 saturation <90% or 
pO2 <60 mmHg) should be admitted to hospital whatever their PSI score.
§ If blood pH has been measured, and score is 90, then patient may be 
considered for management as an outpatient with oral therapy.
¶ In tropical Australia, melioidosis and Acinetobacter baumannii infection 
should be considered in all patients in risk class V and those with risk factors in 
risk classes III and IV.
Clinical features suggest pneumonia
Chest x-ray
No consolidation Consolidation
Consider other diagnoses Pneumonia likely
Age > 50 years  
Coexisting illness (neoplastic, cerebrovascular, 
renal or liver disease, or congestive cardiac failure)
Physical signs on examination (altered mental state,
pulse  125 bpm, respiratory rate   30 per minute,
systolic blood pressure < 90 mmHg, or temperature
< 35C or  40C).
Determine level of risk using initial PSI 
criteria (Box 4)
Further assessment in hospital emergency
department
Serum electrolyte and urea levels
Full blood examination
Arterial blood gas analysis (or O2 saturation plus
venous pH)
Glucose level (if diabetes is known or suspected)
Blood cultures
Gram stain and culture of sputum (if available)
Review of chest x-ray
†
None of above criteria 
= risk class I (lowest risk)
One or more of 
above criteria = higher risk













oral amoxycillin plus 
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pseudomallei (melioidosis) or A. baumannii and thus may
require different initial empirical therapy. Patients with CAP
in risk classes III or IV who also have risk factors for these
infections (eg, diabetes, chronic airways disease, high
alcohol intake or renal disease) should receive initial therapy
with regimens that include intravenous gentamicin plus
ceftriaxone (2 g for adults). All patients in risk class V should
receive regimens that include intravenous gentamicin plus
meropenem, if available. The regimen needs to be further
refined if one of these pathogens is identified.24
Supportive care
For patients with hypoxaemia, continuous oxygen therapy
should be provided with the aim of maintaining O2
saturation over 95% (or 90% in those with chronic
hypercapnia). Patients with asthma or chronic obstructive
pulmonary disease require optimisation of their bronchodi-
lator therapy. Adequate hydration is also important, but care
should be taken in older patients to avoid fluid overload,
which may worsen gas exchange. Specific therapy for cardiac
failure may be required. Occasionally, patients with severe
pneumonia develop acute renal failure, which may require
temporary dialysis. Changes in renal function should be kept
in mind when selecting antibiotics and antibiotic doses.
Patients with chest pain require pain control to facilitate
coughing and clearance of secretions, but routine chest
physiotherapy is probably not useful unless secretions are
copious. Adequate humidification of inspired air and
suctioning of the large airways in patients with reduced
consciousness or poor cough may also be useful. 
Follow-up
Patients need to be monitored clinically to ensure that their
condition improves on treatment. Daily review for the first
few days is recommended. Improvement on chest x-ray is
often slow and should not be used to monitor initial
response to treatment. Improved sense of well-being,
reduced temperature and reduced respiratory rate are
expected in most patients in 24 to 72 hours, but may take
longer if pneumonia is severe.14 Failure to improve should
prompt review of the case. Antibiotic failure itself is not
usually the reason.
If the patient’s condition does not improve, the following
should be considered:
■ Is the diagnosis correct? (Results of diagnostic tests
should be rechecked.)
■ Is the patient taking the antibiotics?
7: Case report — management of community-acquired pneumonia
Presentation: A 66-year-old man, accompanied by his wife, presented 
to his general practitioner with three days of fever, cough and increasing 
breathlessness. He had a past history of smoking, chronic airways disease
and type 2 diabetes. He was born in Australia, had no recent history of travel 
overseas or to northern Australia, or of influenza-like illness.
Examination: The patient was not able to give a coherent history. His 
temperature was 38.0C; blood pressure, 140/70; pulse rate, 120 bpm; and
respiratory rate, 30 per minute. He had widespread coarse lung crackles and 
wheeze but no focal signs. 
Investigations: Clinical assessment suggested pneumonia. An urgent chest 
X-ray showed consolidation in the left lingular and right lower lobe. As the 
clinical picture suggested severe pneumonia, the patient was referred 
immediately to the nearest hospital emergency department for further 
assessment.
Risk assessment and management: The patient had at least two characteristics 
preventing classification as low risk (age > 50 years and confusion). Sputum 
Gram stain and culture, blood cultures, measurement of serum urea and 
electrolyte levels, liver function tests, full blood examination and Legionella 
urinary antigen tests were ordered. Based on results, PSI score was calculated 
as 126, or risk class IV (see table at right). High flow oxygen was begun to 
keep O2 saturation >95%, and fluid and insulin were given for diabetes. 
Intravenous penicillin (1.8 g, 4-hourly) plus oral doxycycline (200 mg oral 
loading dose, then 100mg twice daily) were prescribed. 
Day 2: Legionella urinary antigen test gave a positive result, and the local 
public health unit was notified. As the patient was still unwell, oral doxycycline 
was replaced with intravenous erythromycin (1 g, 6-hourly), and penicillin 
was continued. 
Day 3: The patient’s condition began to improve, but fever persisted. 
Day 5: The patient was afebrile for the first time. 
Day 7: His condition had improved further, and therapy was changed to oral 
doxycycline because of phlebitis. Antibiotic treatment was continued until Day 14.
Calculation of PSI score*
Factor Result PSI  score
Patient age 66 years +66
Specified coexisting illness No 0
Signs on examination
Confusion Yes +20
Respiratory rate 28 per min 0
Systolic blood pressure 140 mmHg 0
Temperature 38C 0
Pulse rate 120 bpm 0
Results of investigations
Serum urea level 17 mmol/L +20
Serum sodium level 136 mmol/L 0
Serum glucose level 19.6 mmol/L +10
Haematocrit 40% 0
O2 saturation 86% +10
pH 7.36 0
Pleural effusion No 0
Total 126
*If results of blood tests cannot be obtained rapidly (eg, in 
remote areas), risk can be determined without the PSI score 
(see Box 3). In this case, presence of diabetes, respiratory 
rate > 20 per minute, confusion and multilobar disease on 
x-ray would have suggested that the patient was at significantly 
increased risk of death. 
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■ Would hospital admission and intravenous therapy now
be appropriate?
■ Is there a complication (eg, effusion or empyema)?
■ Is there obstruction (eg, bronchial carcinoma or a foreign
body)?
■ Is the pathogen S. aureus, Pseudomonas spp. or other
gram-negative rod, which may not respond to standard
empirical regimens?
■ Is it tuberculosis?
■ Could the patient have HIV infection?
■ Should the patient be referred to a specialist (eg, for
diagnostic bronchoscopy)? 
Prevention and public health
Annual influenza vaccination and five-yearly pneumococcal
vaccination are recommended for people with risk factors
and all those aged over 65 years.29 For Indigenous people,
who have much higher rates of CAP than the non-
Indigenous population, regular influenza and pneumococcal
vaccination is recommended from the age of 50.29
Legionnaire’s disease, tuberculosis and psittacosis are
notifiable diseases. Suspected cases should be reported
immediately to local public health authorities so that public
health measures can be taken.
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Evidence-based recommendations
■ Certain patient, clinical and laboratory features at presentation 
are independently associated with risk of death from community-
acquired pneumonia14,19 (E32).
■ These features can be used to generate a pneumonia severity 
index which correlates with risk of death, need for hospital 
admission, length of hospital stay and need for intensive care19 
(E32).
■ The pneumonia severity index can be used with caution to guide 
decisions about where and how to manage patients20 (E33).
